Skip to main content
Biopharmaceutical Technology · R&D · Process Development — Bengaluru, India

Advancing biopharmaceutical technologies, from science to scalable solutions.

Theertha Biopharma is a technology-driven biopharmaceutical R&D company developing platforms and processes for biosimilars, recombinant proteins, peptides, exosomes, liposomes and advanced biologics — with CDMO/CRO capabilities for selected programmes.

Start a project Our capabilities
Biosimilars Recombinant proteins & peptides Exosome & liposome platforms Process development & transfer
Our position

Most programmes lose time at the handoffs. We removed them.

The team that develops your clone is the team that characterizes it, scales it, formulates it and transfers it — working from one continuous data package rather than four that have to be reconciled.

2019Founded in Bengaluru
05Integrated services
04Product lines
ISOCertified quality system
Capabilities

Five services. One continuous data package.

Take one, or take the chain. Either way the deliverable is the same: working material, and the documentation that lets you use it.

01 — Capability

Clone development

Microbial and mammalian cloning with complete, regulatory-compliant data packages. Gene synthesis, expression plasmid generation, construct design and characterization.

  • Mammalian and microbial expression systems
  • Gene synthesis and plasmid generation
  • Construct design and characterization
  • Regulatory-ready documentation from day one
Explore
Clone development at Theertha Biopharma
02 — Capability

Process development

Upstream and downstream development engineered for high titre and recovery, built on platform technology that scales predictably from bench to pilot.

  • Upstream and downstream development
  • Platform technology for high titre
  • Scale-up and scale-down modelling
  • Process characterization and control strategy
Explore
Process development at Theertha Biopharma
03 — Capability

Analytical development

Method development, qualification and validation — monograph-based or in-house — supported by orthogonal product characterization.

  • Method development, qualification, validation
  • Orthogonal product characterization
  • Release and stability testing
  • Current-generation instrumentation
Explore
Analytical development at Theertha Biopharma
04 — Capability

Formulation development

Formulation and stability programmes designed to carry a candidate cleanly out of process development and into pre-clinical and clinical supply.

  • Excipient and buffer screening
  • Forced degradation and stability studies
  • Liposome and delivery platform work
  • Container-closure compatibility
Explore
Formulation development at Theertha Biopharma
05 — Capability

Technology transfer

Documentation-first transfer of methods and processes between laboratories and manufacturing sites, structured so nothing is lost at the handoff.

  • Method and process transfer protocols
  • Comparability and bridging studies
  • Site-to-site training and oversight
  • Complete SOP and batch record packages
Explore
Technology transfer at Theertha Biopharma
Collaboration is how this industry moves faster. We bring the platform depth so our partners can spend their time on the one thing only they can do. Theertha Biopharma
Products

Reagents you can build a programme on.

Research and pre-clinical grade material, supplied with the analytical data behind it.

Monoclonal Antibodies

Monoclonal Antibodies

Research and pre-clinical grade IgG for target validation, assay development and biosimilar reference work.

View product
Recombinant Peptides

Recombinant Peptides

Custom and catalog peptides expressed and purified to defined purity thresholds.

View product
Recombinant Enzymes

Recombinant Enzymes

Enzyme reagents with lot-specific activity data for assay, bioprocess and diagnostic use.

View product
Cell & Gene Therapy Reagents

Cell & Gene Therapy Reagents

Reagents supporting vector production and cell-line process development.

View product
Therapeutic focus

Where our work is applied.

01

Oncology

Antibody and protein reagents supporting oncology target validation and biosimilar development.

02

Diabetes

Peptide and analog development work, including GLP-1 class biosimilar programmes.

03

Obesity

Metabolic peptide development and the formulation work these candidates demand.

04

Immunomodulators

Recombinant proteins and enzymes for immunological research and therapeutic development.

Next step

Tell us where your molecule is today.

Discovery, process, or scale-up. Send us the stage and the deadline, and we will come back with the shortest technically sound path — not a capability deck.

Contact the team